Activated prothrombin complex concentrate (Transfusion medicine)
نویسندگان
چکیده
منابع مشابه
More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
The number of patients on antithrombotic treatment due to atrial fibrillation and venous thromboembolism is increasing fast due to an aging population. A growing proportion will be treated with novel oral anticoagulants, the first in clinical use was the direct oral thrombin inhibitor dabigatran (Pradaxa®). A small percentage of the patients on dabigatran will experience serious bleeding or be ...
متن کاملFondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats.
Gilles Corbonnois1,2*; Michèle Martin2,3*; Marie Hacquard3; Bruno Levy2,4; Paul Michel Mertes1,2; Thomas Lecompte2,3,5**; Gérard Audibert1,2** 1University Hospital of Nancy, Department of Anaesthesia and Intensive Care Medicine, Nancy, France; 2INSERM 961, Contrat Avenir INSERM, Nancy, France; 3University Hospital of Nancy, Haematology Laboratory – Haemostasis, Nancy, France; 4Hospital Universi...
متن کاملThe reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
BACKGROUND An increasing number of patients are treated with direct-acting oral anticoagulants (DOACs), but the optimal way to reverse the anticoagulant effect is not known. Specific antidotes are not available and prothrombin complex concentrate (PCC), activated PCC (aPCC) and recombinant factor VIIa (rFVIIa) are variously used as reversal agents in case of a major bleeding. We aimed to determ...
متن کاملProthrombin Complex Concentrate, a General Antidote for Oral Anticoagulation
Prothrombin complex concentrate (PCC) is used for the rapid reversal of vitamin K antagonist (VKA) anticoagulation. PCC is also applicable in situations requiring rapid reversal of anticoagulation by non-vitamin K antagonist direct thrombin and factor Xa inhibitor oral anticoagulants (NOACs), thereby making PCC a general antidote for oral anticoagulation. In this chapter, the composition of dif...
متن کاملProthrombin complex concentrate-related thrombotic risk following anticoagulation reversal.
Dear Sirs, We read with interest the report of the meta-analysis performed by Dentali et al. on the adverse events after prothrombin complex concentrate (PCC) use for the emergency reversal of vitamin K antagonists (1). The authors identified a low incidence of thrombotic events and a non-significant difference between fourand three-factor PCCs at 1.8% and 0.7%, respectively. We do not wish to ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Thrombosis and Hemostasis
سال: 2010
ISSN: 1880-8808,0915-7441
DOI: 10.2491/jjsth.21.506